news
New Phase III data presented for first time demonstrate tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy,…
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
